The Regression of Liver Fibrosis and Risk for Hepatocellular Carcinoma (ROLFH) Study
This study aims to demonstrate that patients with chronic hepatitis C (CHC) and B (CHB) experiencing regression of liver cirrhosis after effective antiviral therapy have decreased risk for hepatocellular carcinoma (HCC). Primary aim is to determine the incidence of HCC in patients with cirrhosis secondary to CHC and CHB, after treatment is provided, and to identify the magnitude of the decreased risk for HCC in patients experiencing regression of fibrosis. As a secondary aim, environmental risk factors for HCC development will be sought, in order to determine a subset of patients in whom it will be safe to stop surveillance.
Chronic Hepatitis C
Chronic Hepatitis B
Other: Regression of fibrosis
Other: Specific risk factors related to hepatocellular carcinoma
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||The Regression of Liver Fibrosis and Risk for Hepatocellular Carcinoma (ROLFH) Study|
- Hepatocellular carcinoma [ Time Frame: 3 years ] [ Designated as safety issue: No ]According to standard imaging surveillance protocol, and confirmatory CT/MRI/biopsy
- Risk factors for hepatocellular carcinoma [ Time Frame: Change from baseline to 3 years ] [ Designated as safety issue: No ]Positive family history of liver cancer, BMI, active/previous smoking, active/previous alcohol consumption, caffeine consumption in diet, diabetes mellitus, use of drugs for chronic medical conditions
- Profile with lowest risk for hepatocellular carcinoma [ Time Frame: Change from baseline to 3 years ] [ Designated as safety issue: No ]Composite of regression of fibrosis plus other specific conditions decreasing incidence of hepatocellular carcinoma to <1.5% / year
- Regression of liver fibrosis [ Time Frame: Change from baseline to 3 years ] [ Designated as safety issue: No ]According to Fibrotest/Fibrosure and transient elastography
Biospecimen Retention: Samples With DNA
Serum, plasma, PBMC for DNA isolation
|Study Start Date:||July 2015|
|Estimated Study Completion Date:||December 2019|
|Estimated Primary Completion Date:||June 2019 (Final data collection date for primary outcome measure)|
Regression of fibrosis
Group conformed by patients experiencing improvement in the noninvasive markers of fibrosis, Fibrotest/Fibrosure and transient elastography, while enrolled in the study.
Other: Regression of fibrosis
Regression of fibrosis will be defined by assessing yearly evolution of noninvasive markers in patients who received antiviral therapy before start of the study, and by comparing baseline markers before start of antiviral therapy to those on subsequent yearly visits in patients prospective recruited (>50% of cases).
Other Name: FibroTest, FibroSure, FibroScan (transient elastography)Other: Specific risk factors related to hepatocellular carcinoma
Such as: family history of liver cancer; body mass index; alcohol, smoking and recreational drug use status; dietary habits, including use of caffeinated drinks; comorbidities such as type 2 diabetes mellitus; use of medications for other chronic diseases such as statins and angiotensin-converting enzyme inhibitors.
No regression of fibrosis
Group conformed by patients not showing the predefined improvement in the noninvasive markers of fibrosis, Fibrotest/Fibrosure and transient elastography, while enrolled in the study.
Cirrhosis is the final pathway of chronic liver disease, and up to 30% of patients develop hepatocellular carcinoma (HCC) within 5 years of diagnosis of cirrhosis. Worldwide, chronic hepatitis C (CHC) and B (CHB) account for the majority of cases of cirrhosis. Successful antiviral treatment results in regression of fibrosis in the majority of patients. Surveillance programs for early detection of HCC mandate the use of imaging (ultrasound/CT-scan) every 6 months. It has been shown in CHC and CHB that the risk of HCC is greatly reduced after viral disease is eradicated/inactive. However, the impact that regression of fibrosis and other factors could have in abating the incidence of HCC has not been systematically investigated. Currently, all patients with eradicated/inactive viral disease continue to be enrolled in HCC surveillance programs, generating anxiety in patients and very high costs to our healthcare system. Fibrotest (FT) and transient elastography (TE) are noninvasive tools proven to be useful for serial assessment of liver fibrosis.
OBJECTIVES: The proposed hypothesis is that patients with regression of liver fibrosis have decreased risk for HCC. Primary aim is to determine the incidence of HCC in patients with cirrhosis secondary to CHC and CHB, during the 3-7 years after treatment is provided, and to identify the magnitude of the decreased risk for HCC in patients experiencing regression of fibrosis. As a secondary aim, environmental risk factors for HCC development will be sought, in order to determine a subset of patients in whom it will be safe to stop surveillance.
METHODS: Patients 18-70 year-old with cirrhosis will be identified from hepatology clinics in 4 academic centers in North America. FT/TE will be obtained before the start of antivirals and yearly thereafter (prospective arm). A retrolective arm of all patients treated no earlier than Jan/2009 will also be included. In this group, baseline FT/TE will be performed off treatment (CHC) or after initial phase of therapy (CHB), and yearly thereafter. During baseline and yearly visits other factors possibly affecting HCC development will be investigated (family history, comorbidities, BMI, diet, etc.). Patients will be classified as having or having not undergone regression of fibrosis after a 3-year follow up, depending on FT and TE evolution. During follow up, all patients will undergo 6-month imaging as part of their routine HCC surveillance. Based on power calculations, enrollment should stop after 924 patients have been recruited. Kaplan-Meier and Cox regression models will be used to analyze data.
PATIENT OUTCOMES: ROLFH study uses state-of-the-art noninvasive markers of liver fibrosis to test whether reversed fibrosis decreases the risk of HCC. We believe this study will lead to a better understanding of HCC risk factors, improved patient counseling and decision making, optimized screening and allocation of health resources, and decreased healthcare costs.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01831037
|Contact: Andres Duarte-Rojo, MD, MScemail@example.com|
|Contact: Matthew G Deneke, MDfirstname.lastname@example.org|
|United States, Arkansas|
|University of Arkansas for Medical Sciences||Not yet recruiting|
|Little Rock, Arkansas, United States, 72211|
|Contact: Andres Duarte-Rojo, MD, MSc 501-686-5175 email@example.com|
|Contact: Matthew G Deneke, MD 501-686-5175 firstname.lastname@example.org|
|Sub-Investigator: Jonathan A Dranoff, MD|
|Sub-Investigator: Paula K Roberson, PhD|
|Sub-Investigator: Matthew G Deneke, MD|
|Principal Investigator: Andres Duarte-Rojo, MD, MSc|
|United States, North Carolina|
|University of North Carolina at Chapel Hill||Not yet recruiting|
|Chapel Hill, North Carolina, United States, 27599|
|Contact: Jama M Darling, MD 919-966-2516 email@example.com|
|Contact: Sidney Barritt, MD 919-966-2516 firstname.lastname@example.org|
|Principal Investigator: Jama M Darling, MD|
|Sub-Investigator: Sidney Barritt, MD|
|University of Calgary||Not yet recruiting|
|Calgary, Alberta, Canada, T2N 4Z6|
|Contact: Robert P Myers, MD, MPH email@example.com|
|Principal Investigator: Robert P Myers, MD, MPH|
|University of Toronto||Not yet recruiting|
|Toronto, Ontario, Canada, M5T 2S8|
|Contact: Jordan J Feld, MD, MPH +(416) 603-6230 firstname.lastname@example.org|
|Principal Investigator: Jordan J Feld, MD, MPH|
|Principal Investigator:||Andres Duarte-Rojo, MD, MSc||University of Arkansas|
|Principal Investigator:||Jonathan A Dranoff, MD||University of Arkansas|